BIO-RAD LABORATORIES -CL B (BIO.B) Stock Fundamental Analysis
USA - NYSE:BIO.B - US0905721082 - Common Stock
284.875 USD
+37.82 (+15.31%)
We assign a fundamental rating of 4 out of 10 to BIO.B. BIO.B was compared to 57 industry peers in the Life Sciences Tools & Services industry. BIO.B has an excellent financial health rating, but there are some minor concerns on its profitability. BIO.B has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
BIO.B had positive earnings in the past year.
In the past year BIO.B had a positive cash flow from operations.
In multiple years BIO.B reported negative net income over the last 5 years.
In the past 5 years BIO.B always reported a positive cash flow from operatings.
1.2 Ratios
BIO.B has a better Return On Assets (3.12%) than 70.18% of its industry peers.
Looking at the Return On Equity, with a value of 4.47%, BIO.B is in the better half of the industry, outperforming 70.18% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 2.36%, BIO.B is in line with its industry, outperforming 59.65% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for BIO.B is significantly below the industry average of 14.93%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.12% | ||
| ROE | 4.47% | ||
| ROIC | 2.36% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
BIO.B's Profit Margin of 12.49% is fine compared to the rest of the industry. BIO.B outperforms 78.95% of its industry peers.
Looking at the Operating Margin, with a value of 11.30%, BIO.B is in the better half of the industry, outperforming 68.42% of the companies in the same industry.
BIO.B's Operating Margin has been stable in the last couple of years.
BIO.B's Gross Margin of 53.00% is in line compared to the rest of the industry. BIO.B outperforms 57.89% of its industry peers.
In the last couple of years the Gross Margin of BIO.B has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.3% | ||
| PM (TTM) | 12.49% | ||
| GM | 53% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BIO.B is destroying value.
BIO.B has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, BIO.B has less shares outstanding
The debt/assets ratio for BIO.B is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.18 indicates that BIO.B is not in any danger for bankruptcy at the moment.
BIO.B has a better Altman-Z score (3.18) than 70.18% of its industry peers.
The Debt to FCF ratio of BIO.B is 3.46, which is a good value as it means it would take BIO.B, 3.46 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 3.46, BIO.B is doing good in the industry, outperforming 73.68% of the companies in the same industry.
A Debt/Equity ratio of 0.17 indicates that BIO.B is not too dependend on debt financing.
BIO.B has a Debt to Equity ratio of 0.17. This is comparable to the rest of the industry: BIO.B outperforms 57.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | 3.46 | ||
| Altman-Z | 3.18 |
ROIC/WACC0.23
WACC10.09%
2.3 Liquidity
BIO.B has a Current Ratio of 5.12. This indicates that BIO.B is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.12, BIO.B is in the better half of the industry, outperforming 68.42% of the companies in the same industry.
A Quick Ratio of 3.67 indicates that BIO.B has no problem at all paying its short term obligations.
The Quick ratio of BIO.B (3.67) is better than 64.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.12 | ||
| Quick Ratio | 3.67 |
3. Growth
3.1 Past
The earnings per share for BIO.B have decreased by -7.11% in the last year.
BIO.B shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.84% yearly.
The Revenue has decreased by -0.33% in the past year.
The Revenue has been growing slightly by 2.11% on average over the past years.
EPS 1Y (TTM)-7.11%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%-16.08%
Revenue 1Y (TTM)-0.33%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%2.06%
3.2 Future
BIO.B is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -2.55% yearly.
Based on estimates for the next years, BIO.B will show a small growth in Revenue. The Revenue will grow by 1.48% on average per year.
EPS Next Y-5.49%
EPS Next 2Y0.38%
EPS Next 3Y3.62%
EPS Next 5Y-2.55%
Revenue Next Year0.65%
Revenue Next 2Y1.77%
Revenue Next 3Y2.31%
Revenue Next 5Y1.48%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
BIO.B is valuated quite expensively with a Price/Earnings ratio of 28.32.
Compared to the rest of the industry, the Price/Earnings ratio of BIO.B indicates a somewhat cheap valuation: BIO.B is cheaper than 66.67% of the companies listed in the same industry.
BIO.B is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.40, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 27.42, which means the current valuation is very expensive for BIO.B.
Based on the Price/Forward Earnings ratio, BIO.B is valued a bit cheaper than the industry average as 68.42% of the companies are valued more expensively.
BIO.B's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.94.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.32 | ||
| Fwd PE | 27.42 |
4.2 Price Multiples
80.70% of the companies in the same industry are more expensive than BIO.B, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.18 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)3.61
EPS Next 2Y0.38%
EPS Next 3Y3.62%
5. Dividend
5.1 Amount
No dividends for BIO.B!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:BIO.B (9/19/2025, 8:04:00 PM)
284.875
+37.82 (+15.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners89.73%
Inst Owner Change0%
Ins Owners3.84%
Ins Owner ChangeN/A
Market Cap7.71B
Analysts78.18
Price Target369.39 (29.67%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)44.02%
Min EPS beat(2)38.97%
Max EPS beat(2)49.07%
EPS beat(4)4
Avg EPS beat(4)40.05%
Min EPS beat(4)0.1%
Max EPS beat(4)72.05%
EPS beat(8)7
Avg EPS beat(8)26.32%
EPS beat(12)8
Avg EPS beat(12)16.87%
EPS beat(16)12
Avg EPS beat(16)20.5%
Revenue beat(2)2
Avg Revenue beat(2)2.99%
Min Revenue beat(2)1.11%
Max Revenue beat(2)4.87%
Revenue beat(4)3
Avg Revenue beat(4)1.42%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)-1.19%
Revenue beat(12)3
Avg Revenue beat(12)-1.6%
Revenue beat(16)6
Avg Revenue beat(16)-0.34%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)17.09%
EPS NQ rev (3m)-22.41%
EPS NY rev (1m)14.35%
EPS NY rev (3m)11.99%
Revenue NQ rev (1m)3.05%
Revenue NQ rev (3m)-1.08%
Revenue NY rev (1m)2.91%
Revenue NY rev (3m)2.82%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.32 | ||
| Fwd PE | 27.42 | ||
| P/S | 3.02 | ||
| P/FCF | 22.18 | ||
| P/OCF | 14.42 | ||
| P/B | 1.08 | ||
| P/tB | 1.25 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.06
EY3.53%
EPS(NY)10.39
Fwd EY3.65%
FCF(TTM)12.84
FCFY4.51%
OCF(TTM)19.76
OCFY6.94%
SpS94.39
BVpS263.44
TBVpS227.28
PEG (NY)N/A
PEG (5Y)3.61
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.12% | ||
| ROE | 4.47% | ||
| ROCE | 2.99% | ||
| ROIC | 2.36% | ||
| ROICexc | 2.75% | ||
| ROICexgc | 3.12% | ||
| OM | 11.3% | ||
| PM (TTM) | 12.49% | ||
| GM | 53% | ||
| FCFM | 13.61% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexcg growth 3Y8.21%
ROICexcg growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score6
Asset Turnover0.25
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | 3.46 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 7.33% | ||
| Interest Coverage | -6.2 | ||
| Cash Conversion | N/A | ||
| Profit Quality | 108.94% | ||
| Current Ratio | 5.12 | ||
| Quick Ratio | 3.67 | ||
| Altman-Z | 3.18 |
F-Score6
WACC10.09%
ROIC/WACC0.23
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.11%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%-16.08%
EPS Next Y-5.49%
EPS Next 2Y0.38%
EPS Next 3Y3.62%
EPS Next 5Y-2.55%
Revenue 1Y (TTM)-0.33%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%2.06%
Revenue Next Year0.65%
Revenue Next 2Y1.77%
Revenue Next 3Y2.31%
Revenue Next 5Y1.48%
EBIT growth 1Y-15.48%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year33.54%
EBIT Next 3Y15.21%
EBIT Next 5Y7.17%
FCF growth 1Y125.65%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y86.4%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%